2-氯联苯-3-羧酸 | 168619-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯联苯-3-羧酸
• 中文别名: -氯-3-联苯甲酸；2'-氯联苯-3-羧酸；-氯联苯-3-羧酸
• 英文名称: 2'-chloro-[1,1'-biphenyl]-3-carboxylic acid
• 英文别名: 2'-Chlorobiphenyl-3-carboxylic acid；3-(2-chlorophenyl)benzoic acid
• CAS: 168619-03-2
• 化学式: C₁₃H₉ClO₂
• mdl: MFCD03424596
• 分子量: 232.666
• InChiKey: XGEMSZNXYHULJU-UHFFFAOYSA-N

物化性质

• 沸点：
  400.8±28.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2-氯联苯-3-羧酸 在 4-二甲氨基吡啶 、 potassium cyanide 、 羟胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 (2S,3S)-2-((2'-chloro-[1,1'-biphenyl]-3-yl)formamido)-N-hydroxy-3-methylpentanamide
  参考文献：
  名称：

  Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors

  摘要：

  The botulinum neurotoxin (BoNT) is the most lethal protein known to man causing the deadly disease botulinum. The neurotoxin, composed of a heavy (HC) and light (LC) chain, work in concert to cause muscle paralysis. A therapeutic strategy to treat individuals infected with the neurotoxin is inhibiting the catalytic activity of the BoNT LC. We report the synthesis, inhibition study and computational docking analysis of novel small molecule BoNT/A LC inhibitors. A structure activity relationship study resulted in the discovery of D-isoleucine functionalized with a hydroxamic acid on the C-terminal and a biphenyl with chlorine at C- 2 connected by a sulfonamide linker at the N-terminus. This compound has a measured IC50 of 0.587 mu M for the BoNT/A LC. Computational docking analysis indicates the sulfonamide linker adopts a geometry that is advantageous for binding to the BoNT LC active site. In addition, Arg363 is predicted to be involved in key binding interactions with the scaffold in this study.

  DOI：

  10.1016/j.bmc.2020.115659
• 作为产物：
  描述：

  3-溴苯甲酸甲酯 在 四(三苯基膦)钯 、 sodium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 24.17h， 生成 2-氯联苯-3-羧酸
  参考文献：
  名称：

  Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors

  摘要：

  The botulinum neurotoxin (BoNT) is the most lethal protein known to man causing the deadly disease botulinum. The neurotoxin, composed of a heavy (HC) and light (LC) chain, work in concert to cause muscle paralysis. A therapeutic strategy to treat individuals infected with the neurotoxin is inhibiting the catalytic activity of the BoNT LC. We report the synthesis, inhibition study and computational docking analysis of novel small molecule BoNT/A LC inhibitors. A structure activity relationship study resulted in the discovery of D-isoleucine functionalized with a hydroxamic acid on the C-terminal and a biphenyl with chlorine at C- 2 connected by a sulfonamide linker at the N-terminus. This compound has a measured IC50 of 0.587 mu M for the BoNT/A LC. Computational docking analysis indicates the sulfonamide linker adopts a geometry that is advantageous for binding to the BoNT LC active site. In addition, Arg363 is predicted to be involved in key binding interactions with the scaffold in this study.

  DOI：

  10.1016/j.bmc.2020.115659

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• [EN] HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE MER
  申请人：DONG A SOCIO HOLDINGS CO LTD

  公开号：WO2018071343A1

  公开（公告）日：2018-04-19

  Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, R24, X, L, n and p are as defined in the specification, are useful for treating or preventing Mer tyrosine kinase receptor modulated disease or conditions. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

  式(I)的化合物及其药学上可接受的盐，其中A、R1、R2、R3、R4、R5、R6、R7、R24、X、L、n和p如规范中定义的那样，可用于治疗或预防Mer酪氨酸激酶受体调节的疾病或症状。还描述了式(I)的化合物的药物组合物，以及使用这些化合物和组合物的方法。
• [EN] NOVEL SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] NOUVEAUX INHIBITEURS SÉLECTIFS DE LA 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
  申请人：DSM IP ASSETS BV

  公开号：WO2017012890A1

  公开（公告）日：2017-01-26

  The present invention relates to novel selective 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and the use thereof to prevent age-induced skin structure and function defects.

  本发明涉及新型选择性11-β-羟基类固醇脱氢酶1（11β-HSD1）抑制剂及其用途，用于预防年龄诱导的皮肤结构和功能缺陷。
• [EN] NOVEL ANTIFUNGAL PYRIDINYLHYDRAZIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS ANTIFONGIQUES DE PYRIDINYLHYDRAZIDE
  申请人：DAE WOONG PHARMA

  公开号：WO2015034271A1

  公开（公告）日：2015-03-12

  The present invention relates to novel pyridinylhydrazide derivatives and a method for manufacturing the same. The pyridinylhydrazide derivatives of the present invention have excellent antifungal and fungicidal activities, and thus will be useful for the prevention and treatment of various fungal infections. Additionally, the pyridinylhydrazide derivatives of the present invention, unlike other fungicidal preparations, can be orally administered.

  本发明涉及新型吡啶基肼衍生物及其制备方法。本发明的吡啶基肼衍生物具有优异的抗真菌和杀真菌活性，因此可用于预防和治疗各种真菌感染。此外，与其他真菌杀菌制剂不同，本发明的吡啶基肼衍生物可以口服。
• [EN] GUANIDINE DERIVATIVES AS INHIBITORS OF Na/H EXCHANGE IN CELLS<br/>[FR] DERIVES DE GUANIDINE, UTILISES COMME INHIBITEURS DE L'ECHANGE DE Na/H DANS LES CELLULES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1994026709A1

  公开（公告）日：1994-11-24

  (EN) Guanidine derivatives of formula (I), wherein Y is N or C-R1 (in which R1 is hydrogen, lower alkyl, hydroxy, protected hydroxy, etc.), R2 is hydrogen, aryl which may have one suitable substituent, aryloxy, etc., R3 is hydrogen, lower alkoxy, hydroxy, protected hydroxy, etc., Z is N or C-R4 (in which R4 is hydrogen, carboxy, protected carboxy, nitro, halogen, hydroxy(lower)alkyl, etc.), and W is N or C-R12 (in which R12 is hydrogen, lower alkoxy, nitro, hydroxy or protected hydroxy), and pharmaceutically acceptable salts thereof which are useful as a medicament.(FR) L'invention se rapporte à des dérivés de guanidine, représentés par la formule (I), où Y représente N ou C-R1 (où R1 représente hydrogène, alkyle inférieur, hydroxy, hydroxy protégé, etc.), R2 représente hydrogène, aryle qui peut comporter un substituant approprié, aryloxy, etc., R3 représente hydrogène, alcoxy inférieur, hydroxy, hydroxy protégé, etc., Z représente N ou C-R4 (où R4 représente hydrogène, carboxy, carboxy protégé, nitro, halogène, hydroxy alkyle (inférieur), etc.), et W représente N ou C-R12 (où R12 représente hydrogène, alcoxy inférieur, nitro, hydroxy ou hydroxy protégé), ainsi qu'à des sels pharmaceutiquement acceptables de ces dérivés, utiles comme médicaments.

  (中) 公式(I)中的guanidine衍生物，其中Y是N或C-R1（其中R1是氢，低烷基，羟基，保护羟基等），R2是氢，芳基（可能有一个适当的取代基），芳氧基等，R3是氢，低烷氧基，羟基，保护羟基等，Z是N或C-R4（其中R4是氢，羧基，保护羧基，硝基，卤素，羟基（低）烷基等），W是N或C-R12（其中R12是氢，低烷氧基，硝基，羟基或保护羟基），以及其药学上可接受的盐，可用作药物。